Awakn Life Sciences, which offers psychedelic medical applications in the treatment of mental health conditions including addiction, announced on March 9 that it had obtained a substantial amount of proprietary research data on MDMA and ketamine molecules.
The data acquisition represents five years of research and makes Awakn the first psychotherapy clinic in the United Kingdom to use ketamine in the process of treating mental health patients, particularly for addiction but also other conditions.
In addition to the procurement of the research data, Professor David Nutt became Awakn’s head of research, leading Awakn’s molecule development program.
“I am delighted to be able to bring the research forward, to lead this activity in Awakn, and to significantly accelerate the development of new compounds to better treat addiction,” said Nutt.
The clinic will offer one round of low-dosage treatments of ketamine, in combination with talk therapy, for about £6,000, according to a March 15 British Broadcasting Corporation (BBC) article.
The [ketamine] therapy will treat people with depression and anxiety disorders, including obsessive-compulsive disorder, generalized anxiety disorder and post-traumatic stress disorder.
Awakn is incorporating psychedelic treatment into mainstream healthcare through its clinics, continued research, and ecosystems.
Awakn also has locations in Manchester, Dublin and continental Europe.
George Scorsis 